Ask AI
ProCE Banner Activity

Beyond BCMA: How GPRC5D-Targeted Therapy Fits into Multiple Myeloma Care Today

Podcast

Targeted therapies are becoming more common treatment options for patients with multiple myeloma. Specifically, there have been emerging clinical data on GPRC5D-directed bispecific antibodies for patients with relapsed and refractory disease. In this podcast, 2 experts in the field discuss how they are using GPRC5D-directed therapies in their practice, including treatment planning, patient selection, adverse event management, and how new combination strategies may affect practice.

Released: July 15, 2026

Review Activity

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

This activity is supported by an educational grant from Johnson & Johnson.

Johnson & Johnson

Target Audience

This activity is designed for hematologists, oncologists, and other healthcare professionals who care for patients with multiple myeloma.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Describe the biologic rationale for targeting GPRC5D in multiple myeloma and its role within the evolving immunotherapy landscape

  • Apply evidence-based strategies for sequencing GPRC5D bispecific antibodies within current treatment paradigms

  • Identify and manage key safety and tolerability considerations unique to GPRC5D-directed bispecific antibody therapy

Financial Disclosures

Primary Author

Jesus G. Berdeja, MD: researcher: AstraZeneca, Bristol Myers Squibb, C4 Therapeutics, Caribou, Genentech, GSK, Gracell, Ichnos, Johnson & Johnson, Juno, K36 Therapeutics, Karyopharm, Kite, Pfizer, Roche, Sanofi; consultant/advisor/speaker: AstraZeneca, Bristol Myers Squibb, Galapagos, Johnson & Johnson, Karyopharm, Kite, Kyowa Kirin, Pfizer, Regeneron, Roche.

Amrita Krishnan, MD, FACP: consultant/advisor/speaker: AbbVie, AstraZeneca, Bristol Myers Squibb, Johnson & Johnson, Pfizer, Roche, Sanofi; publicly traded stocks/stock options: Arcellx, Bristol Myers Squibb.